Montserrat Milà

Montserrat Milà

Auto-generated profile, based on publicly available information

Montserrat Milà

Biochemistry and Molecular Genetics Department, Hospital Clinic, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1998 in The Lancet
Verified
Journal Article
Open access
XEXavier Estivill
Xavier Estivill
PFPaolo Fortina
Paolo Fortina
SSSaul Surrey
Saul Surrey
RRRaquel Rabionet
Raquel Rabionet
SMSalvatore Melchionda
Salvatore Melchionda
PGPaolo Gasparini
Paolo Gasparini
Hearing impairment affects one infant in 1000 and 4% of people aged younger than 45 years. Congenital deafness is inherited or apparently sporadic. We have shown previously that DFNB1 on chromosome 13 is a major locus for recessive deafness in about 80% of Mediterranean families and that the connexin-26 gene gap junction protein beta2 (GJB2) is mutated in DFNB1 families. We investigated mutations in the GJB2 gene in familial and sporadic cases of deafness. We obtained DNA samples from 82 families from Italy and Spain with recessive non-syndromic deafness and from 54 unrelated participants with apparently sporadic congenital deafness. We analysed the coding region of the GJB2 gene for mutations. We also tested 280 unrelated people from the general populations of Italy and Spain for the frameshift mutation 35delG. 49% of participants with recessive deafness and 37% of sporadic cases had mutations in the GJB2 gene. The 35delG mutation accounted for 85% of GJB2 mutations, six other mutations accounted for 6% of alleles, and no changes in the coding region of GJB2 were detected in 9% of DFNB1 alleles. The carrier frequency of mutation 35delG among people from the general population was one in 31 (95% CI one in 19 to one in 87). Mutations in the GJB2 gene are a major cause of inherited and apparently sporadic congenital deafness. Mutation 35delG is the most common mutation for sensorineural deafness. Identification of 35delG and other mutations in the GJB2 gene should facilitate diagnosis and counselling for the most common genetic form of deafness.

15 April 2009 in European Journal of Human Genetics
Verified
Journal Article
Closed access
LRLaia Rodriguez-Revenga
Laia Rodriguez-Revenga
IMIrene Madrigal
Irene Madrigal
JPJavier Pagonabarraga
Javier Pagonabarraga
MXMar Xunclà
Mar Xunclà
CBCelia Badenas
Celia Badenas
MMMontserrat Milà
Montserrat Milà

6 September 2001 in Oncogene
Verified
Journal Article
Closed access
Helen RizosHelen Rizos
Helen Rizos
SPSusana Puig
Susana Puig
CBCelia Badenas
Celia Badenas
JMJosep Malvehy
Josep Malvehy
ADArtur P Darmanian
Artur P Darmanian
RKRichard F Kefford
Richard F Kefford

1 October 2017 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
MMMontserrat Mila
Montserrat Mila
MAMaria Isabel Alvarez-Mora
Maria Isabel Alvarez-Mora
IMIrene Madrigal
Irene Madrigal
LRLaia Rodriguez‐Revenga
Laia Rodriguez‐Revenga

30 July 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
AWAnne Wheeler
Anne Wheeler
DBDonald Bailey
Donald Bailey
EBElizabeth M. NA Berry-Kravis
Elizabeth M. NA Berry-Kravis
JGJan Greenberg
Jan Greenberg
MLMolly Losh
Molly Losh
RHRandi Hagerman
Randi Hagerman
Changes in the fragile X mental retardation 1 gene (FMR1) have been associated with specific phenotypes, most specifically those of fragile X syndrome (FXS), fragile X tremor/ataxia syndrome (FXTAS), and fragile X primary ovarian insufficiency (FXPOI). Evidence of increased risk for additional medical, psychiatric, and cognitive features and conditions is now known to exist for individuals with a premutation, although some features have been more thoroughly studied than others. This review highlights the literature on medical, reproductive, cognitive, and psychiatric features, primarily in females, that have been suggested to be associated with changes in the FMR1 gene. Based on this review, each feature is evaluated with regard to the strength of evidence of association with the premutation. Areas of need for additional focused research and possible intervention strategies are suggested.

1 May 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SPSusana Puig
Susana Puig
JMJosep Malvehy
Josep Malvehy
CBCelia Badenas
Celia Badenas
ARAnna Ruiz
Anna Ruiz
DJDolores Jimenez
Dolores Jimenez
MMMontserrat Milà
Montserrat Milà
Purpose: We have studied a consecutive case series of patients with multiple primary melanoma (MPM) for the involvement of the melanoma susceptibility loci CDKN2A and CDK4. Patients and Methods: One hundred four MPM patients (81 patients with two primary melanomas, 14 with three, five with four, one with five, two with six, and one with seven) were included. Results: Seven different CDKN2A germline mutations were identified in 17 patients (16.3%). In total, we identified 15 CDKN2A exon 2, one exon 1α missense mutation, and one exon 1β frameshift mutation. The age of onset was significantly lower and the number of primary melanomas higher in patients with mutations. CDKN2A mutations were more frequent in patients with familial history of melanoma (35.5%) compared with patients without (8.2%), with a relative risk (RR) of 4.32 (95% CI, 1.76 to 10.64; P = .001), and in patients with more than two melanomas (39.1%) compared with patients with only two melanomas (10%) with an RR of 3.29 (95% CI, 1.7 to 6.3; P = .002). The A148T polymorphism was more frequent in patients with MPMs than in the control population (P = .05). A variant of uncertain significance, A127S, was also detected in one patient. No CDK4 mutations were identified, suggesting that it has a low impact in susceptibility to MPM. Conclusion: MPM patients are good candidates for CDKN2A mutational screening. These patients and some of their siblings should be included in a program of specific follow-up with total body photography and digital dermoscopy, which will result in the early detection of melanoma in this subset of high-risk patients and improve phenotypic characterization.